Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Current Pulmonology Reports
Erschienen in: Current Pulmonology Reports 3/2015

01.09.2015 | Interstitial Lung Disease (E Alhamed, Section Editor)

Rheumatoid arthritis-associated interstitial lung disease

verfasst von: Sultana Abdulaziz

Erschienen in: Current Pulmonology Reports | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Rheumatoid-associated interstitial lung disease (RA-ILD) is an important extra-articular manifestation of rheumatoid arthritis (RA), contributing to significant morbidity and mortality. Mortality is increased by 3-folds in RA-ILD patients in contrast with those without ILD. RA-ILD is frequently observed in males, and the risk of developing ILD is associated with older age at time of RA onset, male gender, and greater RA disease severity. Usual interstitial pneumonia (UIP) being the most common, with the worst prognosis. RA-ILD patients with UIP pattern tend to be older, more likely to be males, and have a more significant smoking history and worse survival. In contrast, those without the UIP pattern tend to be younger, more likely to be women, and have a less significant smoking history. This review discusses the diagnosis and therapeutic option in the management of RA-ILD.
Literatur
1.••
Cavagna L et al. The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. BioMed Res Int. 2013;2013:13. Elaborating smoking as a independant risk factor with the presence of rheumatoid factor and anti-cyclic citrullinated peptide as risk factors for the development of RA-ILD. CrossRef
2.
Helmick CG et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15–25.PubMedCrossRef
3.
Myasoedova E et al. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study. J Rheumatol. 2011;38(6):983–9.PubMedCentralPubMedCrossRef
4.
Bradley B et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63 Suppl 5:v1–58.PubMed
5.
Philip Ellman REB. “Rheumatoid disease” with joint and pulmonary manifestations. Br Med J. 1948;6(2):816–20.CrossRef
6.•
Cutolo M, Kitas GD, van Riel PL. Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. Semin Arthritis Rheum. 2014;43(4):479–88. A article including 118 randomized cohorts and large (>100) sample size studying the burden of extra-articular involvement in RA.PubMedCrossRef
7.••
Kelly CA et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics—a large multicentre UK study. Rheumatology (Oxford). 2014;53(9):1676–82. A large multicenter UK study examining predictive and prognostic factors for the development of RA-ILD and the physiological and radiological characterictics of RA-ILD.CrossRef
8.••
Olivas-Flores EM. Interstitial lung disease in rheumatoid arthritis: current concepts in pathogenesis, diagnosis and therapeutics. World J Rheumatol. 2015;5(1):1–22. This review analyzes current evidence regarding the epidemiology, pathogenesis, diagnosis and treatment of RA-ILD.CrossRef
9.
Sihvonen S et al. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol. 2004;33(4):221–7.PubMedCrossRef
10.
Bongartz T et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583–91.PubMedCentralPubMedCrossRef
11.
Kinoshita Y, Sakamoto A, Hidaka K. Organizing pneumonia preceding rheumatoid arthritis. Case Rep Pulmonol. 2014;2014:758619.PubMedCentralPubMed
12.••
de Lauretis A, Veeraraghavan S, Renzoni E. Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011;8(1):53–82. The article emphazises the most common pattern of RA-ILD characterized by high frequency of usual interstitial pneumonia.PubMed
13.
Pérez-Dórame R et al. Rheumatoid arthritis-associated interstitial lung disease: lung inflammation evaluated with high resolution computed tomography scan is correlated to rheumatoid arthritis disease activity. Reumatol Clín. 2015;11(01):12–6.PubMedCrossRef
14.
Bergstrom U et al. Pulmonary dysfunction, smoking, socioeconomic status and the risk of developing rheumatoid arthritis. Rheumatology (Oxford). 2011;50(11):2005–13.CrossRef
15.
Koduri G et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford). 2010;49(8):1483–9.CrossRef
16.
Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med. 2012;106(11):1591–9.PubMedCrossRef
17.
Charles PJ, Sweatman MC, Marckwick JR, et al. HLA-B40: a marker for susceptibility to lung disease in rheumatoid arthritis. Dis Markers. 1991;9:97–101.PubMed
18.
Spagnolo P, Grunewald J, du Bois RM. Genetic determinants of pulmonary fibrosis: evolving concepts. Lancet Respir Med. 2014;2(5):416–28.PubMedCrossRef
19.
Agusti C. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277–304.CrossRef
20.
Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127(6):2019–27.PubMedCrossRef
21.
Tsuchiya Y et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J. 2011;37(6):1411–7.PubMedCrossRef
22.••
Assayag D, Lee JS, King Jr TE. Rheumatoid arthritis associated interstitial lung disease: a review. Medicina (B Aires). 2014;74(2):158–65. The article reviews the proposed pathogenesis, risk factors for RA-ILD, the diagnosis, treatment and prognosis.
23.
Kim EJ et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322–8.PubMedCrossRef
24.
Skare TL, Nakano I, Escuissiato DL, Batistetti R, Rodrigues Tde O, Silva MB, Pulmonary changes on high-resolution computed tomography of patients with rheumatoid arthritis and their association with clinical, demographic, serological and therapeutic variables. Rev Bras Reumatol. Jul-Aug. 2011;51(4):325-30, 336-7.
25.
Dawson JK et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax. 2001;56(8):622–7.PubMedCentralPubMedCrossRef
26.
Travis WD et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.PubMedCrossRef
27.••
Assayag D, Urbania TH, Colby TV, Kang BH, Ryu JH, King TE, et al. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology. 2014;270(2):583–8. The study emphasizes the correlation of HRCT with the histopathologic pattern in RA-ILD.
28.
Raghu G, Lynch D. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir Med. 2014;2(4):277–84.PubMedCrossRef
29.
Biederer J et al. Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol. 2004;14(2):272–80.PubMedCrossRef
30.
Zhang D, Liu Y. Surgical lung biopsies in 418 patients with suspected interstitial lung disease in China. Intern Med. 2010;49(12):1097–102.PubMedCrossRef
31.•
Moazedi-Fuerst F, et al. Sonographic assessment of interstitial lung disease in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus. Clin Exp Rheumatol, 2015. The use of transthoracic ultrasound of the lung in diagnosis of ILD in rheumatic disease.
32.•
Moazedi-Fuerst FC et al. Ultrasound screening for interstitial lung disease in rheumatoid arthritis. Clin Exp Rheumatol. 2014;32(2):199–203.
33.••
Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43(5):613–26. A recent systemic literature review of ILD in RA associated with non-biologics disease modifying antirheumatic drugs and biologicals.PubMedCrossRef
34.
Cohen JM, Miller A, Spiera H. Interstitial pneumonitis complicating rheumatoid arthritis. Sustained remission with azathioprine therapy. Chest. 1977;72(4):521–4.PubMedCrossRef
35.
Fischer A, Brown K, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640–6.PubMedCentralPubMedCrossRef
36.
Nannini C et al. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther. 2008;10(5):R124.PubMedCentralPubMedCrossRef
37.••
Keir GJ et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19(3):353–9. A retrospective study of 50 patients with severe, progressive ILD treated with rituximab between 2010-2012. The study showed rituximab may offer an therapeutic intervention in patients unresponsive to conventional immunosuppression.PubMedCrossRef
38.
Keir GJ et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J. 2012;40(3):641–8.PubMedCrossRef
39.
Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. J Korean Med Sci. 2002;17(2):270–3.PubMedCentralPubMedCrossRef
40.
Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Respir J. 2004;24(4):708.PubMedCrossRef
41.
Antoniou KM et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol. 2007;25(1):23–8.PubMed
42.••
Jani M et al. The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol. 2014;10(5):284–94. The paper reviews the evidence for the comparative pulomary safety of anti-TNF agents and non-TNF targeted biological therapy.PubMedCrossRef
43.
Moua T et al. Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia. Respir Res. 2014;15(1):154.PubMedCentralPubMedCrossRef
44.•
Yazdani A et al. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Heart Lung Transplant. 2014;33(5):514–20. A retrospective study examining post-transtlant surival in RA-ILD patients  compared with IPF and scleroderma -associated ILD showing ra-ild and IPF  had siimalr survival after lung transplant.PubMedCrossRef
Metadaten
Titel
Rheumatoid arthritis-associated interstitial lung disease
verfasst von
Sultana Abdulaziz
Publikationsdatum
01.09.2015
Verlag
Springer US
Erschienen in
Current Pulmonology Reports / Ausgabe 3/2015
Elektronische ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-015-0121-9

Weitere Artikel der Ausgabe 3/2015

Current Pulmonology Reports 3/2015 Zur Ausgabe

Bronchiectasis (G Tino, Section Editor)

Bronchiectasis in adults: epidemiology, assessment of severity and prognosis

Interstitial Lung Disease (E Alhamed, Section Editor)

Role of broncho: alveolar lavage in approaching interstitial lung diseases

Interstitial Lung Disease (E Alhamad, Section Editor)

The role of serological testing in idiopathic interstitial pneumonia: a rheumatologist perspective

Bronchiectasis (G Tino, Section Editor)

The challenge of pulmonary nontuberculous mycobacterial infection

Interstitial Lung Disease (E Alhamed, Section Editor)

Biomarkers in interstitial lung disease: moving towards composite indexes and multimarkers?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise